CoChat

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

Knudsen, Lotte Bjerre, Pridal, Lone · 1996 · European Journal of Pharmacology
Cited by 248

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0014-2999(96)00795-9

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 18

  1. Adelhorst, 1994, Structure-activity studies of GLP-1, J. Biol. Chem., 269, 6275, 10.1016/S0021-9258(17)37366-0 · DOI · Paper page
  2. Cottrell, 1992, Insulinotropic effect of GLP-1-(7–37) in non-insulin dependent diabetes mellitus patients: a study of dose and glucose dependency, Clin. Res., 40, 734A
  3. Deacon, 1995, Both subcutaneous and intravenously administered GLP-1 are rapidly degraded from the N-terminus in type-2 diabetic patients and in healthy subjects, Diabetes, 44, 1126, 10.2337/diabetes.44.9.1126 · DOI · Paper page
  4. Drejer, 1991, Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells, Diabetes, 40, 1588, 10.2337/diabetes.40.11.1488 · DOI
  5. Frohman, 1989, Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma, J. Clin. Invest., 83, 1533, 10.1172/JCI114049 · DOI · Paper page
  6. Gallwitz, 1994, Structure-activity characterization of glucagon-like peptide-1, Eur. J. Biochem., 225, 1151, 10.1111/j.1432-1033.1994.1151b.x · DOI · Paper page
  7. Gallwitz, 1995, Binding characteristics of N-terminal GIP/GLP-1 hybrid peptides, Endocrinol. Metab., 2, 39
  8. Gefel, 1990, GLP-1 analogs: effects on insulin secretion and cAMP formation, Endocrinology, 126, 2164, 10.1210/endo-126-4-2164 · DOI · Paper page
  9. Grandt, 1994, Is GLP-1-(9–36) amide an endogenous antagonist at GLP-1 receptors?, Digestion, 55, 302
  10. Hvidberg, 1994, Effect of GLP-1 on hepatic glucose production in healthy man, Metabolism, 43, 104, 10.1016/0026-0495(94)90164-3 · DOI · Paper page
  11. Jörnvall, 1981, Amino acid sequence and heterogeneity of gastric inhibitory polypeptide, FEBS Lett., 123, 205, 10.1016/0014-5793(81)80288-8 · DOI · Paper page
  12. Pridal, 1995, Comparison of sandwich ELISA and RIA for detection of exogenous GLP-1-(7–36) amide in plasma, J. Pharm. Biomed. Anal., 13, 841, 10.1016/0731-7085(95)01312-9 · DOI
  13. Pridal, 1996, Glucagon-like peptide-1-(7–37) has a larger volume of distribution than glucagon-like peptide-1-(7–36) amide in dogs and is degraded more quickly in vitro by dog plasma, Eur. J. Drug Metab. Pharmacokin., 21, 51, 10.1007/BF03190278 · DOI
  14. Robberecht, 1988, Secretin receptors in human pancreatic membranes, Pancreas, 3, 529, 10.1097/00006676-198810000-00004 · DOI
  15. Rorstad, 1990, Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide, Mol. Pharmacol., 37, 971
  16. Schmidt, 1986, Characterization of the insulinotropic activity of fragments derived from gastric inhibitory polypeptide, Diabetologia, 29, 591A
  17. Suzuki, 1989, Comparison of the effects of various C-terminal and N-terminal fragment peptides of GLP-1 on insulin and glucagon release from isolated rat pancreas, Endocrinology, 125, 3109, 10.1210/endo-125-6-3109 · DOI · Paper page
  18. Thorell, 1971, Enzymatic iodination of polypeptide with (125I) to high specific activity, Biochim. Biophys. Acta, 251, 363, 10.1016/0005-2795(71)90123-1 · DOI · Paper page

Cited by

See all 248

Metadata

Authors
Knudsen, L. B., & Pridal, L.
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
1996-12
Volume
318
Issue
2-3
Pages
429-435
ISSN
0014-2999 (ISSN-L)
OpenAlex
W2061202826
Cited by
248
References
6
FWCI
4.78
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.